European urology最新文献

{"title":"IDH1 Mutations Are Associated with Favorable Outcomes in Prostate Cancer.","authors":"Luka Cavka, Subhiksha Nandakumar, Qingqing Wu, Nihar J Mehta, Zeynep Irem Ozay, Anika Begum, Ritika Kundra, Erin Shannon, Shayan S Nazari, Mark G Evans, Norm Smith, Andrew Elliott, Benzion Samueli, Samson W Fine, Jie-Fu Chen, Philip W Kantoff, Pedro Isaacsson Velho, Hao Wang, David E Sanin, Eliezer M Van Allen, Neeraj Agarwal, Wassim Abida, Tamara L Lotan, Nikolaus Schultz, Emmanuel S Antonarakis, Laura A Sena","doi":"10.1016/j.eururo.2026.03.014","DOIUrl":"10.1016/j.eururo.2026.03.014","url":null,"abstract":"<p><p>Prostate cancer with isocitrate dehydrogenase 1 (IDH1) or isocitrate dehydrogenase 2 (IDH2) mutation appears to be a unique molecular subclass, but its associated clinical features have not been previously described. Here, we performed a retrospective analysis of clinical and molecular features of prostate cancer with IDH1 p.R132 or IDH2 p.R172 mutations. A series of 99 IDH1-mutated and 12 IDH2-mutated cases was identified using genomics databases at multiple institutions. An IDH1/2 wild-type control cohort was generated with matched clinical features at diagnosis. IDH-mutated cases frequently presented with localized disease (91%), but exhibited high tumor stage (42% T3) and grade (54% grade group 5). Compared with matched controls, patients with IDH1 mutations exhibited longer overall survival (hazard ratio [HR], 0.16; 95% confidence interval [CI], 0.04-0.68; p = 0.01), metastasis-free survival (HR, 0.22; 95% CI, 0.09-0.58; p = 0.002), and progression-free survival on hormonal therapy (HR, 0.35; 95% CI, 0.16-0.76; p = 0.036). IDH1-mutant cases were enriched for concurrent activating mutations of FOXA1 and CTNNB1 and tended to lack TMPRSS2-ERG fusions, SPOP mutations, and RB1 alterations. IDH1 mutations were associated with global transcriptional repression and evidence of metabolic and epigenetic reprogramming. These results depict IDH-mutant prostate cancer as a subtype that can present with high tumor stage and grade, but is associated with favorable outcomes.</p>","PeriodicalId":94000,"journal":{"name":"European urology","volume":" ","pages":""},"PeriodicalIF":25.2,"publicationDate":"2026-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13178107/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147936621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of Lymph Node-Positive Renal Cell Carcinoma: Updated Recommendations from the European Association of Urology Renal Cell Carcinoma Guidelines Panel.","authors":"Umberto Capitanio, Patricia Zondervan, Riccardo Campi, Teele Kuusk, Tobias Klatte, Yasmin Abu-Ghanem, Stephanie Bonn, David J Breen, Saeed Dabestani, Milan Hora, Lars Lund, Lorenzo Marconi, Carlotta Palumbo, Geraldine Pignot, Maxine Tran, Rose Woodward, Cristina Suárez, Tom Powles, Jens Bedke, Axel Bex","doi":"10.1016/j.eururo.2026.04.001","DOIUrl":"https://doi.org/10.1016/j.eururo.2026.04.001","url":null,"abstract":"<p><p>Lymph node-positive renal cell carcinoma is a heterogeneous condition. Patients with bulky or multiple nodal metastases often behave like those with metastatic disease and may benefit more from upfront systemic therapy than from surgery alone.</p>","PeriodicalId":94000,"journal":{"name":"European urology","volume":" ","pages":""},"PeriodicalIF":25.2,"publicationDate":"2026-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147935905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"10-yr Survival and Toxicity Outcomes of Stereotactic Body Radiotherapy for Prostate Cancer: A Nonrandomized Clinical Trial.","authors":"Robert M Meier, Nima Aghdam, Alan C Beckman, Shermian A Woodhouse, Shirnett K Williamson, Najeeb Mohideen, John J Dombrowski, Irving D Kaplan","doi":"10.1016/j.eururo.2026.04.029","DOIUrl":"https://doi.org/10.1016/j.eururo.2026.04.029","url":null,"abstract":"<p><p>Stereotactic body radiotherapy (SBRT) is established as standard therapy for organ-confined prostate cancer (PC) based on 5-yr phase 2-3 outcomes, but 10-yr data are lacking. Here, we report 10-yr results of a trial conducted at 21 centers. Patients were treated from January 2008 to April 2010. SBRT was delivered on a noncoplanar robotic platform with real-time motion management, to a total dose of 40 Gy in five fractions. Adjuvant hormone therapy was not allowed. Late toxicities (>90 d) were assessed with Common Terminology Criteria for Adverse Events version 3 (CTCAE v3). Biochemical failure is defined as nadir+2. Relapses are defined as biochemical or clinical failure or salvage/systemic PC therapy. Out of 310 evaluable patients, median age 68 yr; 172 were low-risk (LR), and 138 patients were intermediate-risk (IR). Median follow-up was 9 yr. Ten-yr cumulative grade 3 gastrointestinal (GI) or genitourinary (GU) toxicities were 1.4% and 1.5% in the LR and IR cohorts, respectively. There were no grade 4-5 events observed. Ten year grade 2+ GI and GU toxicity rates were 2.1% and 14% respectively. Overall survival in 10 yr was 84%. Overall, relapse-free survival (RFS) was 90%; 94% in the LR cohort, 86% in the IR cohort, and 92% versus 77% in the favorable vs unfavorable intermediate subgroups. In this multi-institutional trial, the 10-yr follow-up demonstrates that prostate SBRT yields minimal toxicity and favorable RFS.</p>","PeriodicalId":94000,"journal":{"name":"European urology","volume":" ","pages":""},"PeriodicalIF":25.2,"publicationDate":"2026-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147864869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comprehensive Genomic and Transcriptomic Characterization of Matched Primary and Recurrent Tumors in High-risk Localized Renal Cell Carcinoma.","authors":"Wenxin Xu, Brian I Rini, Laurence Albiges, Xiaobin Tang, Hartmut Koeppen, Axel Bex, Cristina Suárez, Robert Uzzo, Viraj Master, Jose A Karam, Habib Hamidi, Zoe June Assaf, Sarita Dubey, Erik T Goluboff, Corey Carter, Romain Banchereau, Mahrukh A Huseni, Sumanta Kumar Pal","doi":"10.1016/j.eururo.2026.03.023","DOIUrl":"https://doi.org/10.1016/j.eururo.2026.03.023","url":null,"abstract":"<p><p>Recurrence after nephrectomy in high-risk localized renal cell carcinoma is common, but the genomic and transcriptomic differences between primary and recurrent tumors are not well understood. In the IMmotion010 trial, patients were randomized to receive adjuvant atezolizumab versus placebo. Tumor tissue was collected at pre-treatment baseline (n = 754) and subsequently at the time of recurrence (n = 80). We performed matched transcriptomic (n = 80) and genomic (n = 52) analyses on primary versus recurrent samples. Using previously described transcriptomic classifications, resected primary tumors had a higher proportion of angiogenic and small nucleolar RNA transcriptomic signatures and lower proportion of T-effector/proliferative and stromal/proliferative signatures compared with published metastatic cohorts. Sites of recurrence exhibited upregulation of signatures related to cell proliferation, fatty acid synthesis, and stromal biology, including matrix and fibroblasts. Comparing treatment arms, tumors that recurred in placebo-treated patients demonstrated increased B cell and macrophage signatures, while tumors that recurred despite adjuvant atezolizumab showed downregulation of major histocompatibility complex (MHC)-I. Although requiring further clinical validation, the latter finding may substantiate scientifically a potential rationale for transitioning to vascular endothelial growth factor (VEGF)-inhibition after adjuvant checkpoint inhibition.</p>","PeriodicalId":94000,"journal":{"name":"European urology","volume":" ","pages":""},"PeriodicalIF":25.2,"publicationDate":"2026-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147793034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Robot-assisted Laparoscopic W-shaped Ileocystoplasty in Children.","authors":"Amane-Allah Lachkar, Alexis Arnaud, Camille Duchesne, Matthieu Peycelon, Florence Julien-Marsollier, Annabel Paye, Alaa El-Ghoneimi","doi":"10.1016/j.eururo.2025.11.023","DOIUrl":"https://doi.org/10.1016/j.eururo.2025.11.023","url":null,"abstract":"<p><strong>Background and objective: </strong>Robot-assisted bladder augmentation in children is rarely utilized across Europe. Performing this procedure robotically with an ileal loop \"W\" configuration is innovative. We analyzed the preliminary results of our experience in robotic-assisted laparoscopic W-shaped ileocystoplasty (RALAWI) in children.</p><p><strong>Methods and surgical procedure: </strong>A prospective bicentric study included all patients who had RALAWI (2020-2024). The procedures were performed using the DaVinci Xi robot. The statistical analysis was descriptive (median [range]) and comparative. Thirteen patients were included (age 9.5 [5-16] yr, weight 31 [19-99] kg), and followed up for 15.5 (12-50) mo. Etiologies included the following: neuropathic bladder (nine cases), bladder exstrophy (two cases), rhabdomyosarcoma (one case), and bilateral ectopic ureters (one case).</p><p><strong>Key findings and limitations: </strong>All procedures were performed intra-abdominally without conversion. The median operative time and length of stay were 670 (450-930) min and 12 (6-30) d, respectively. The associated procedures were extraserosal appendicovesicostomy (APV; eight cases), bladder neck reconstruction (six cases), bladder neck closure (one case), and bilateral ureteral reimplantation (two cases). Six patients had multiple abdominal surgeries previously. Four patients had complications at <30 d: urinary anastomotic leakage (N = 2, IIIB according to Clavien-Dindo), abscess (N = 1, IIIA), and ventriculoperitoneal shunt dysfunction (N = 1, IIIB). Five patients had nine complications at >30 d: stoma leakage (three cases, IIIB), bladder stone (one case, IIIB), difficult catheterization (two cases, IIIB), and ileocystoplasty perforation (one case, IIIB, and one case, IVA). None had APV stenosis. Postoperative bladder capacity was significantly higher (170 vs 350 ml; p < 0.01). All patients achieved continence.</p><p><strong>Conclusions and clinical implications: </strong>To our knowledge, this is the first report of robot-assisted ileocystoplasty in children with a W-shape reconfiguration. It is feasible even after multiple surgeries, offering potential benefits for patients with fragile abdominal wall. The technique requires further refinements to reduce operative time and early postoperative complications.</p>","PeriodicalId":94000,"journal":{"name":"European urology","volume":" ","pages":""},"PeriodicalIF":25.2,"publicationDate":"2025-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145784041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: External Validation of the Rotterdam Prostate Cancer Risk Calculator and Comparison with Stockholm3 for Prostate Cancer Diagnosis in a Swedish Population-based Screening Cohort.","authors":"Christian D Fankhauser, Marian S Wettstein, Christoph Würnschimmel, Maarten van Smeden, Noel W Clarke","doi":"10.1016/j.eururo.2024.05.002","DOIUrl":"10.1016/j.eururo.2024.05.002","url":null,"abstract":"","PeriodicalId":94000,"journal":{"name":"European urology","volume":" ","pages":"187-188"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140961322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: Alonso Garcia-Ruiz, Carlos Macarro, Francesca Zacchi, et al. Whole-body Magnetic Resonance Imaging as a Treatment Response Biomarker in Castration-resistant Prostate Cancer with Bone Metastases: The iPROMET Clinical Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.02.016.","authors":"A.R. Padhani, Frédéric Lecouvet, G. Petralia, Dow-Mu Koh","doi":"10.1016/j.eururo.2024.04.035","DOIUrl":"https://doi.org/10.1016/j.eururo.2024.04.035","url":null,"abstract":"","PeriodicalId":94000,"journal":{"name":"European urology","volume":"51 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141058405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing novel multimodality therapy for prostate cancer, combining radiotherapy, vascular-targeted photodynamic therapy, and anti-CD73 immunotherapy","authors":"Hanna Sjoberg, S. Macklin, Yiannis Philippou, Emma Murphy, Iain D. C. Tullis, Keaton Jones, Stephen M. Stribbling, Dina Preise, Lilach Agemy, Tamar Yechezkel, Amato J. Giaccia, Ian G. Mills, Ruth J. Muschel, Borivoj Vojnovic, Avigdor Scherz, Freddie C. Hamdy, R.J. Bryant","doi":"10.1016/s0302-2838(24)01644-0","DOIUrl":"https://doi.org/10.1016/s0302-2838(24)01644-0","url":null,"abstract":"","PeriodicalId":94000,"journal":{"name":"European urology","volume":"85 1","pages":"S2204-S2204"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147914856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}